Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk (NYSE:NVO) has entered a clinical supply agreement with Veru to test a combination of Wegovy and enobosarm in an obesity trial focused on older adults.
The company also presented new semaglutide data at the American Diabetes Association Scientific Sessions on health effects beyond weight loss.
The stock most recently closed at $42.96, with the share price down 18.0% year to date and down 41.2% over the past year.
Novo Nordisk, trading under NYSE:NVO, is drawing attention as it extends its obesity and cardiometabolic pipeline with both combination therapy research and fresh semaglutide data. The share price is $42.96, with the stock down 18.0% year to date and down 41.2% over the past year, and up 9.7% over five years. This provides useful context for these new clinical developments. For investors tracking obesity and diabetes treatments, these latest moves offer additional data points on how the company is positioning its therapies.
The Veru partnership centers on whether pairing Wegovy with enobosarm can address muscle and bone health concerns in older adults living with obesity, while the ADA data explores semaglutide’s potential health effects beyond weight loss. Readers may want to watch how these trials and findings translate into regulatory discussions, potential label changes, and future study designs, as those outcomes often shape how a cardiometabolic portfolio evolves over time.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
NYSE:NVO Earnings & Revenue Growth as at Jun 2026
We’ve flagged 3 risks for Novo Nordisk. See which could impact your investment.
The clinical supply partnership with Veru gives Novo Nordisk a relatively low-cost way to test whether combining Wegovy with enobosarm can address concerns around muscle and bone loss for older adults with obesity. Novo Nordisk is not funding or running the PLATEAU trial and does not own enobosarm, but the right of first negotiation keeps the door open if results are encouraging. At the same time, the semaglutide data presented at the ADA conference positions the GLP-1 franchise in a broader obesity-related disease setting, with exploratory signals across conditions like sleep apnea, asthma, hypertension, and liver health. For investors comparing Novo Nordisk with Eli Lilly, Pfizer, and other large-cap drug companies working on weight-loss therapies, this news highlights an approach that leans on combination options and potential health benefits beyond weight loss alone. Against a share price that is down 18.0% year to date and down 41.2% over 12 months, the partnership and ADA updates may be viewed as part of how the company is responding to tougher GLP-1 competition and clinical setbacks, while trying to keep Wegovy and semaglutide central to obesity and cardiometabolic treatment pathways.
The Risks and Rewards Investors Should Consider
Analysts have flagged that Novo Nordisk has a high level of debt, which can limit flexibility if pricing pressure on GLP-1 drugs intensifies.
Earnings quality is affected by a high level of non cash items, so headline profitability may not fully reflect underlying cash generation.
The stock is described as trading at 52.8% below one estimate of fair value, which some investors may see as providing a margin of safety if the GLP-1 portfolio delivers.
Earnings grew by 16.6% over the past year, showing that profitability has been moving in the right direction despite competition and guidance cuts.
What To Watch Going Forward
From here, focus on key readouts and milestones. For the Veru partnership, the design, enrollment progress, and later results from the PLATEAU Phase 2b trial will help show whether a Wegovy plus enobosarm combination can support muscle and functional outcomes in older adults. For semaglutide, watch how the ADA data on conditions like sleep apnea and liver health feeds into future trial design, regulatory discussions, and potential label-expansion plans. It is also worth tracking how Novo Nordisk positions oral Wegovy and other pipeline assets against Eli Lilly and other competitors in GLP-1 therapies, and whether management updates financial guidance or capital allocation plans as these programs evolve.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com